PBA
Paradigm Biocapital Advisors’s Viridian Therapeutics VRDN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.3M | Buy |
2,741,576
+646,497
| +31% | +$9.04M | 1.64% | 19 |
|
|
2025
Q1 | $28.2M | Buy |
2,095,079
+275,000
| +15% | +$3.71M | 1.29% | 20 |
|
|
2024
Q4 | $34.9M | Sell |
1,820,079
-1,075,610
| -37% | -$20.6M | 1.21% | 21 |
|
|
2024
Q3 | $65.9M | Sell |
2,895,689
-660
| -0% | -$15K | 2.23% | 13 |
|
|
2024
Q2 | $37.7M | Sell |
2,896,349
-2,135,071
| -42% | -$27.8M | 1.44% | 22 |
|
|
2024
Q1 | $88.1M | Buy |
5,031,420
+236,932
| +5% | +$4.15M | 3.1% | 15 |
|
|
2023
Q4 | $104M | Buy |
4,794,488
+1,112,741
| +30% | +$24.2M | 4.89% | 7 |
|
|
2023
Q3 | $56.5M | Buy |
3,681,747
+1,266,491
| +52% | +$19.4M | 3.83% | 12 |
|
|
2023
Q2 | $57.5M | Buy |
2,415,256
+329,558
| +16% | +$7.84M | 4.44% | 7 |
|
|
2023
Q1 | $53.1M | Buy |
2,085,698
+334,531
| +19% | +$8.51M | 5.03% | 8 |
|
|
2022
Q4 | $51.2M | Buy |
1,751,167
+114,956
| +7% | +$3.36M | 6% | 6 |
|
|
2022
Q3 | $33.6M | Buy |
1,636,211
+329,642
| +25% | +$6.76M | 4.47% | 8 |
|
|
2022
Q2 | $15.1M | Buy |
1,306,569
+50,518
| +4% | +$584K | 3.01% | 13 |
|
|
2022
Q1 | $23.2M | Buy |
1,256,051
+47,000
| +4% | +$869K | 6.14% | 6 |
|
|
2021
Q4 | $23.9M | Buy |
+1,209,051
| New | +$23.9M | 6.83% | 4 |
|